Background
Brian Rifkin
Is REACT (Renal Autologous Cell Therapy) the ...

This week, we will discuss the use of renal autologous cell therapy (REACT) in diabetic kidney disease.

Is REACT (Renal Autologous Cell Therapy) the “fifth pillar” in diabetic kidney disease?
Background
Brian Rifkin
2026 KDIGO Anemia Management Guidelines

This week, we will discuss 2026 KDIGO anemia management in patients with kidney disease

2026 KDIGO Anemia Management Guidelines
Background
Cristina Adriana Popa
To INFINITI and Beyond: SGLT2 Inhibitors in ...

This week, we aim for an INFINITe allograft lifespan. or flozination in kidney transplant.

To INFINITI and Beyond: SGLT2 Inhibitors in Kidney Transplant Patients
Background
Cristina Adriana Popa
POTCAST- K+ Pop and Arrhythmia Drop

This week, we will discuss the POTCAST trial. It is a cardiology trial - but potassium belongs to nephrology.

POTCAST- K+ Pop and Arrhythmia Drop
Background
Brian Rifkin
A VALIANT effort to combat complement disorders ...

This week, we will discuss the VALIANT study, pegcetacoplan in C3G and IC MPGN.

A VALIANT effort to combat complement disorders with pegcetacoplan

VALIANT: El Resumen Visual

El ensayo clínico aleatorizado fase 3 VALIANT demostró que la inhibición proximal de C3 con pegcetacoplan logra una reducción significativamente mayor de la proteinuria en comparación con placebo en pacientes con glomerulopatía C3 (C3G) y glomerulonefritis membranoproliferativa primaria mediada por complejos inmunes (IC-MPGN). Este estudio se basa en estrategias previas de inhibición proximal del complemento y refuerza el papel de las terapias dirigidas a la fisiopatología en la C3G.

No te pierdas el resumen visual creado por Dra. Akshaya Jayachandran y súmate a la discusión en #NephJC por Bluesky 🦋

VALIANT: The Visual Abstract

The VALIANT phase 3 RCT shows that proximal C3 inhibition with pegcetacoplan leads to a significantly greater reduction in proteinuria compared with placebo in patients with C3G and primary immune-complex MPGN. This trial builds on prior upstream complement strategies and strengthens the case for disease-targeted therapy in C3G.

Check out the VA Dr. Akshaya Jayachandran and don´t forget to join #NephJC on bluesky.

LIBERATE-D: El Resumen Visual

En pacientes con lesión renal aguda en diálisis, se evaluó si una estrategia más conservadora impacta en la recuperación renal. ¿Será que menos es más? Únete a la discusión del ensayo clínico LIBERATE-D y, antes, no olvides revisar el resumen visual creado por Sejal Lakhani

Taking the reigns

In April 2014, Swapnil and I launched NephJC—and within weeks we were overwhelmed by the sheer work of running a twice-monthly, Twitter-based journal club. Fortunately, we also had a deep bench of friends on the internet. A rotating cast of brilliant volunteers stepped in, proving the old fortune-cookie wisdom true: many hands make light work.

Over the years, both Swap and I have taken on new responsibilities and new roles. Swap even has a big announcement on the horizon. As NephJC has grown, we’ve had to confront the hardest part of any grassroots digital project: succession. The good news is we’ve been spoiled with talent. Two exceptional leaders have been (not so) quietly steering the ship for the last 18–24 months, so much so that most of you won’t notice any change at all.

Today we’re making it official:

Your new Editors-in-Chief of NephJC are Brian Rifkin and Cristina Popa.

Both are highly decorated graduates from the NSMC. Brian won Rookie of the Year in 2021 and Cristina followed right behind him in 2022. She also tacked on the MVP award in 2024.

Swap and I will still be around, but less.

ORIGIN 3 interim-story: atacicept in IgAN

Check out ORIGIN 3 recap: a 36-week, interim analysis of phase 3 trial of atacicept in IgAN! Thread by NephJC intern Marc Soco.